Medtronic-Supported Clinical Trial Shows ICD Patients Less Likely To Develop Need For Pacing When Device Uses MVP(R) Mode

MVP® (Managed Ventricular Pacing), exclusive programming on Medtronic pacemakers, which is proven to be effective in reducing unnecessary pacing in pacemaker patients, was applied in the MVP Trial of implantable cardioverter-defibrillator (ICD) patients. Data from MVP trial, sponsored by Medtronic, Inc. (NYSE: MDT), were presented today as a late breaking clinical trial at Heart Rhythm 2009, the annual scientific sessions of the Heart Rhythm Society.